Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium‐specific FAK‐kinase dead mice

Focal adhesion kinase (FAK) inhibitors have been developed as potential anticancer agents and are undergoing clinical trials. In vitro activation of the FAK kinase domain triggers autophosphorylation of Y397, Src activation, and subsequent phosphorylation of other FAK tyrosine residues. However, how...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Pathol
Asıl Yazarlar: Alexopoulou, Annika N, Lees, Delphine M, Bodrug, Natalia, Lechertier, Tanguy, Fernandez, Isabelle, D'Amico, Gabriela, Dukinfield, Matthew, Batista, Silvia, Tavora, Bernardo, Serrels, Bryan, Hodivala‐Dilke, Kairbaan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Ltd 2017
Konular:
Original Papers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518444/
https://ncbi.nlm.nih.gov/pubmed/28444899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/path.4911
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller